Capsugel has announced that it will add both pilot and commercial scale micronization capacity at a facility in Quakertown, PA which it acquired as part of its acquisition of Powdersize in January 2016. New equipment and suites are expected to be in operation by January 2017.
By doubling the company’s pilot-scale capacity and adding commercial scale capacity, Capsugel says that it anticipates reducing product lead times by as much as 75%. The new suites will also be designed to handle potent and highly potent compounds.
Capsugel Senior VP Amit Patel said, “Micronization and nano-milling technology is a significant component of Capsugel’s overall service offering, and this investment further strengthens our ability to rapidly advance challenging compounds to clinic and ultimately commercialization.”
Powdersize President Wayne Sigler added, “One of the many reasons we were eager to join Capsugel was the opportunity to become a part of its unique design, development and manufacturing offering. This investment further supports the role of micronization and sub-micronization in compound assessments and product design through commercialization, bringing more benefits to our customers. It also enables us to stay ahead of rising customer demand, so we can help our customers meet aggressive development and clinical timelines.”
Read the Capsugel press release.
